fibrinogen concentrate (human) Injection

Brand(s)
RiaSTAP
Category(s)
other
SPL Type(s)
Plasma Derivative
Master SPL
Csl Behring Gmbh (2013-02-28)
Oldest Current Product
2009-01-16
License(s)
BLA
RxNORM
INJECTION\FIBRINOGEN CONCENTRATE (HUMAN)
SPL Active
INTRAVENOUS\INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION\FIBRINOGEN HUMAN
SPL Moiety
INTRAVENOUS\INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION\FIBRINOGEN HUMAN

product(s) by strength(s)

fibrinogen concentrate (human) 1 mg injection

original product(s)(s)

#idbrandcategorylabelerfirst marketedactive ingredient(s)routedose formapplicationspl
1638330891RiaSTAPBLACsl Behring Gmbh2009-01-16FIBRINOGEN HUMANINTRAVENOUSINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION125317903dc8d0-39da-462c-9dac-004e0c7a26cc

application(s)

#idtitleapprovedtradenamesfda division
1125317Fibrinogen Concentrate (Human)Ria Application2009-01-16STAPCBER

spl(s)

#idtitlecategorytypelabelerlabeler actlast updateversionproduct(s)
1903dc8d0-39da-462c-9dac-004e0c7a26cc (view SPL)These highlights do not include all the information needed to use RiaSTAP safely and effectively. See full prescribing information for RiaSTAP. RiaSTAP, Fibrinogen Concentrate (Human) For Intravenous Use, Lyophilized Powder for Reconstitution Initial U.S. Approval: 2009otherPlasma DerivativeCsl Behring GmbhMANUFACTURE2013-02-2810638330891

Data from: FDAOB, FDAPB, LOINC, MTHSPL, NDFRT, NCIT, RxNORM, UNII